Regulatory delay of Novartis' Galvus also raises concerns about its already approved rival, Merck's Januvia.
[News Source]
[News Source]
Blogosphere: TechnoratiFeedsterBloglines
Bookmark: Del.icio.usSpurlFurlSimpyBlinkDigg


